Mahmoud Hashim
About
Mahmoud Hashim is a scholar working on Hematology, Economics and Econometrics and Statistics and Probability.
According to data from OpenAlex, Mahmoud Hashim has authored 38 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 9 papers in Economics and Econometrics and 9 papers in Statistics and Probability. Recurrent topics in Mahmoud Hashim's work include Multiple Myeloma Research and Treatments (13 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Statistical Methods in Clinical Trials (8 papers). Mahmoud Hashim is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Statistical Methods in Clinical Trials (8 papers). Mahmoud Hashim collaborates with scholars based in United States, Netherlands and Germany. Mahmoud Hashim's co-authors include Bart Heeg, Annette Lam, Jianming He, Margarita Kulakova, Meletios Α. Dimopoulos, Kenneth C. Anderson, Nikhil C. Munshi, Bruno Paiva, Nizar J. Bahlis and Hervé Avet‐Loiseau and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Mahmoud Hashim
34 papers receiving 436 citations
Peers
Mahmoud Hashim
Ghulam Rehman Mohyuddin United States
Jianming He United States
Stefanie Hieke Germany
Kejal Parikh United States
James E. Ward United States
Benjamin A. Derman United States
M Schaafsma Netherlands
Alain Flinois Switzerland
Monique Steijaert Netherlands
Marie-Anne Damiette Smit United States
Citations per year, relative to Mahmoud Hashim Mahmoud Hashim (= 1×)
peers
Ghulam Rehman Mohyuddin
Countries citing papers authored by Mahmoud Hashim
Since
Specialization
Citations
This map shows the geographic impact of Mahmoud Hashim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mahmoud Hashim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mahmoud Hashim more than expected).
Fields of papers citing papers by Mahmoud Hashim
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mahmoud Hashim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mahmoud Hashim. The network helps show where Mahmoud Hashim may publish in the future.
Co-authorship network of co-authors of Mahmoud Hashim
This figure shows the co-authorship network connecting the top 25 collaborators of Mahmoud Hashim. A scholar is included among the top collaborators of Mahmoud Hashim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mahmoud Hashim. Mahmoud Hashim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hashim, Mahmoud, et al.. (2025). Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical Assessments. PharmacoEconomics - Open. 9(4). 597–609.
2.
Roubaud, Guilhem, Gerhardt Attard, Martin Boegemann, et al.. (2024). Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. European Journal of Cancer. 209. 114183–114183.
3.
Kasner, Scott E., et al.. (2024). A matching-adjusted indirect comparison of results from REDUCE and RESPECT—two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke. Journal of Medical Economics. 27(1). 337–343.
4.
Igarashi, Ataru, Shiro Tanaka, Nan Li, et al.. (2024). Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023. Advances in Therapy. 42(1). 52–69.
5.
Tanaka, Shiro, Ataru Igarashi, Nan Li, et al.. (2024). A Targeted Review of Worldwide Indirect Treatment Comparison Guidelines and Best Practices. Value in Health. 27(9). 1179–1190.
6.
Santis, Maria De, Paul Robinson, Suzy Van Sanden, et al.. (2024). Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer. Advances in Therapy. 41(8). 3039–3058.
7.
Fonseca, Rafaël, Thierry Façon, Mahmoud Hashim, et al.. (2023). Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma. The Oncologist. 28(5). e263–e269.
8.
Hashim, Mahmoud, et al.. (2022). How are Companion Diagnostics Considered in Economic Evaluations of Oncology Treatments? A Review of Health Technology Assessments. PharmacoEconomics - Open. 6(5). 637–646.
9.
Fonseca, Rafaël, Thierry Façon, Mahmoud Hashim, et al.. (2021). First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios. Blood. 138(Supplement 1). 118–118.
10.
Moreau, Philippe, Cyrille Hulin, Sonja Zweegman, et al.. (2020). Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching. SHILAP Revista de lepidopterología. 2(1). 66–80.
11.
Hashim, Mahmoud, et al.. (2019). Extrapolating Survival Data Using Historical Trial–Based a Priori Distributions. Value in Health. 22(9). 1012–1017.
12.
Hashim, Mahmoud, et al.. (2019). Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review. PharmacoEconomics - Open. 4(3). 403–418.
13.
Hashim, Mahmoud, et al.. (2018). PCN59 - ASSOCIATION BETWEEN HAZARD RATIOS OF SURROGATE TIME-TO-EVENT ENDPOINTS AND OVERALL SURVIVAL IN ADVANCED/METASTATIC CANCERS. Value in Health. 21. S24–S24.
14.
Hashim, Mahmoud, et al.. (2018). Is There A Consensus Regarding Clinically Relevant Non-Inferiority Margins Used For Key Oncology Endpoints In Non-Inferiority Oncology Trials?. Value in Health. 21. S228–S228.
15.
Henry, Alastair, et al.. (2018). PDB65 - THE COST-EFFECTIVENESS OF METFORMIN IN PRE-DIABETICS: A SYSTEMATIC LITERATURE REVIEW OF HEALTH ECONOMIC EVALUATIONS. Value in Health. 21. S129–S129.
16.
Aly, Markus, Mahmoud Hashim, Bart Heeg, et al.. (2018). Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer—A Systematic Literature Review and Pooling of Individual Participant Data. European Urology Focus. 5(5). 788–798.
17.
Kulakova, Margarita, et al.. (2018). Can duration of response be used as a surrogate endpoint for overall survival in advanced non-small cell lung cancer?. Journal of Clinical Oncology. 36(15_suppl). 9082–9082.
18.
Dimopoulos, Meletios Α., Pieter Sonneveld, Hareth Nahi, et al.. (2017). Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma. Value in Health. 20(9). A408–A408.
19.
Hashim, Mahmoud, et al.. (2017). Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer. Value in Health. 21(1). 9–17.
20.
Hashim, Mahmoud, et al.. (2017). Objective response rate and progression-free survival as surrogate endpoints for overall survival and the impact of crossover and unbalanced post-progression treatments: A systematic review and meta-analysis in first-line therapy of advanced non-small cell lung cancer.. Journal of Clinical Oncology. 35(15_suppl). 9049–9049.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ghulam Rehman Mohyuddin Breakdown of academic impact, for papers by Jianming He Breakdown of academic impact, for papers by Stefanie Hieke Breakdown of academic impact, for papers by Kejal Parikh Breakdown of academic impact, for papers by James E. Ward Breakdown of academic impact, for papers by Benjamin A. Derman Breakdown of academic impact, for papers by M Schaafsma Breakdown of academic impact, for papers by Alain Flinois Breakdown of academic impact, for papers by Monique Steijaert Breakdown of academic impact, for papers by Marie-Anne Damiette Smit